Marrone Bio Innovations Inc (MBII) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MBII Annual Cash Flow →
Cash flow patterns shown here provide context for understanding Marrone Bio Innovations Inc's ability to sustain operations and capital deployment.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2022)
3 Months
(Dec 31 2021) (Sep 30 2021) (Jun 30 2021) (Mar 31 2021)
Operating Activities
Income-7.60
Depreciation & amortization0.89
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-1.41
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.82
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Convertible Notes Increase Decrease In Revenues-
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction-
Investment Income Net Amortization Of Discount And Premium-
Increase Decrease In Deferred Cost Of Product Revenues-
Increase Decrease In Accrued Interest Payable To Related Parties-
Gains Losses On Extinguishment Of Debt Related Party-
Loss On Modification Of Warrants-
Loss On Issuance Of Warrants-
Change In Fair Value Of Contingent Consideration-
Increase Decrease In Lease Liability-
Paids In Kind Interest0.03
Loss On Issuance Of New Warrants-
Changes In Fair Value Of Contingent Consideration-0.03
Change In Inventory Reserves-0.08
Right Of Use Assets Amortization0.31
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable1.10
Increase (Decrease) in Accounts Payable, Trade0.79
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-2.58
Increase (Decrease) in Customer Advances0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.14
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.50
Discontinued operations0.00
Net Cash flow from Operating Activities-8.40
Investing Activities
Capital Expenditures-0.20
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.20
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings10.33
Long-term debt - repayments-12.07
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Net Proceeds From Exercise Of Preferred Stock Warrants-
Net Proceeds From Exercise Of Common Stock Warrants-
Net Settlement Of Stock Options-
Net Settlement Of Options-
Payment Of Financing Costs-
Proceeds From Repayment Of Loans By Employee Stock Ownership Plan0.07
Equity Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-1.67
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-8.59
Total Cash Flow-10.26
4 historic quarters locked

Sign in to unlock the full Marrone Bio Innovations Inc cash flow history.

About Marrone Bio Innovations Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-22-013374

Figures are derived from filed reports and may be restated. Historical data is subject to revision.